jetcityimage/iStock Editorial by way of Getty Photographs
Eli Lilly’s (NYSE:LLY) anti-obesity remedy tirzepatide is thrice extra more likely to trigger a 15% weight discount in comparison with Novo Nordisk’s (NVO) (OTCPK:NONOF) rival remedy, semaglutide, based on a first-of-its-kind real-world examine.
The examine revealed on medRxiv final week forward of peer evaluation represented over 40,000 chubby or overweight adults who started their semaglutide or tirzepatide drugs between Might 2022 and September 2023.
Novo’s (NVO) weight reduction and diabetes medicine, Wegovy and Ozempic, encompass semaglutide, a GLP-1 receptor agonist, because the energetic pharmaceutical ingredient. Lilly’s (LLY) rival therapies, Mounjaro and Zepbound, encompass tirzepatide, a twin GIP/GLP-1 receptor agonist, because the API.
With little or no proof indicating the head-to-head efficacy of two of the preferred drugs on the planet, Truveta, a collective of U.S. healthcare programs, carried out the examine utilizing digital well being information and pharmacy allotting information.
In April, Eli Lilly (LLY) launched a Part 3 trial to guage the effectiveness of the 2 injectables in chubby or overweight sufferers with out sort 2 diabetes. The worldwide trial, involving 700 individuals, is predicted to conclude in H1 2025.
“GLP-1 drugs have already modified the best way physicians deal with sort 2 diabetes and weight problems, however little real-world information exist to check the effectiveness of the 2 most typical drugs, Ozempic and Mounjaro,” Nick Stucky, vice chairman of Truveta Analysis, remarked.
Different highlights of the examine point out that these on tirzepatide have been 2.6 occasions and thrice extra possible than these on semaglutide to realize 10% and 15% weight reduction, respectively.
Moreover, the researchers discovered that, after one yr from beginning remedy, these taking tirzepatide skilled a ~15% imply discount of their physique weight in comparison with ~8% in these taking semaglutide.